scholarly journals Development of a point‐of‐care test for the detection of MDMA in latent fingerprints using Surface Plasmon Resonance and lateral flow technology

2021 ◽  
Author(s):  
Caroline Pollard ◽  
Mark Hudson ◽  
James M. McDonnell ◽  
Paul G. Royall ◽  
Kim Wolff
Biosensors ◽  
2018 ◽  
Vol 8 (4) ◽  
pp. 130 ◽  
Author(s):  
Georgina Ross ◽  
Maria Bremer ◽  
Jan Wichers ◽  
Aart van Amerongen ◽  
Michel Nielen

Lateral Flow Immunoassays (LFIAs) allow for rapid, low-cost, screening of many biomolecules such as food allergens. Despite being classified as rapid tests, many LFIAs take 10–20 min to complete. For a really high-speed LFIA, it is necessary to assess antibody association kinetics. By using a label-free optical technique such as Surface Plasmon Resonance (SPR), it is possible to screen crude monoclonal antibody (mAb) preparations for their association rates against a target. Herein, we describe an SPR-based method for screening and selecting crude anti-hazelnut antibodies based on their relative association rates, cross reactivity and sandwich pairing capabilities, for subsequent application in a rapid ligand binding assay. Thanks to the SPR selection process, only the fast mAb (F-50-6B12) and the slow (S-50-5H9) mAb needed purification for labelling with carbon nanoparticles to exploit high-speed LFIA prototypes. The kinetics observed in SPR were reflected in LFIA, with the test line appearing within 30 s, almost two times faster when F-50-6B12 was used, compared with S-50-5H9. Additionally, the LFIAs have demonstrated their future applicability to real life samples by detecting hazelnut in the sub-ppm range in a cookie matrix. Finally, these LFIAs not only provide a qualitative result when read visually, but also generate semi-quantitative data when exploiting freely downloadable smartphone apps.


RSC Advances ◽  
2018 ◽  
Vol 8 (48) ◽  
pp. 27091-27100 ◽  
Author(s):  
Abbas Motalebizadeh ◽  
Hasan Bagheri ◽  
Sasan Asiaei ◽  
Nasim Fekrat ◽  
Abbas Afkhami

A smartphone-based microfluidic platform was developed for point-of-care (POC) detection using surface plasmon resonance (SPR) of gold nanoparticles (GNPs).


2015 ◽  
Vol 69 (1) ◽  
Author(s):  
Pavel Damborský ◽  
Narayanan Madaboosi ◽  
Virginia Chu ◽  
João P. Conde ◽  
Jaroslav Katrlík

AbstractProstate cancer (PCa) diagnostics can be effectively addressed using sensor-based approaches. Proper selection of biomarkers to be included in biosensors for accurate detection becomes the need of the hour. Such biosensor and biochip technologies enable fast and efficient determination of proteins and provide a remarkable insight into the changes in the protein structure, such as aberrant glycosylation, which can increase the performance, sensitivity and specificity of clinic assays. However, for a thorough comprehension of such complex protein modifications, it is crucial to understand their biospecific interactions. Surface plasmon resonance (SPR), one of the most rapidly developing techniques for measuring real-time quantitative binding affinities and kinetics of the interactions of antigens and antibodies, was chosen as an appropriate tool for this purpose. Herein, experiments on the interactions of antibodies specific against different epitopes of free and complexed prostate-specific antigen (PSA), a prominent PCa biomarker, are presented with two main aims: (i) to continue as lectin glycoprofiling studies and; (ii) to be used in microfluidic immunoassay-based platforms for point-of-care devices. Various PSA-specific antibodies were covalently immobilized on the biochip surface via amine coupling, and free or complexed PSA was injected into the dual-flow channels of the SPR device. Kinetic parameters and affinity constants of these interactions, as well as cross-reactivities of the used antibodies were determined. The sandwich assay for PSA determination was developed employing both primary and secondary anti-PSA antibodies. Sensitivity of the assay was 3.63 nM


2020 ◽  
Author(s):  
Abdelhadi Djaileb ◽  
Benjamin Charron ◽  
Maryam Hojjat Jodaylami ◽  
Vincent Thibault ◽  
Julien Coutu ◽  
...  

We report a surface plasmon resonance (SPR) sensor detecting nucleocapsid antibodies specific against the novel coronavirus 2019 (SARS-CoV-2) in undiluted human serum. When exposed to SARS-CoV-2, the immune system responds by expressing antibodies at levels that can be detected and monitored to identify the patient population immunized against SARD-CoV-2 and support efforts to deploy a vaccine strategically. A SPR sensor coated with a peptide monolayer and functionalized with SARS-CoV-2 nucleocapsid recombinant protein detected anti-SARS-CoV-2 antibodies in the nanomolar range. This bioassay was performed on a portable SPR instrument in undiluted human serum and results were collected within 15 minutes of sample/sensor contact. This strategy paves the way to point-of-care and label-free rapid testing for antibodies.


Author(s):  
Abdelhadi Djaileb ◽  
Benjamin Charron ◽  
Maryam Hojjat Jodaylami ◽  
Vincent Thibault ◽  
Julien Coutu ◽  
...  

We report a surface plasmon resonance (SPR) sensor detecting nucleocapsid antibodies specific against the novel coronavirus 2019 (SARS-CoV-2) in undiluted human serum. When exposed to SARS-CoV-2, the immune system responds by expressing antibodies at levels that can be detected and monitored to identify the patient population immunized against SARD-CoV-2 and support efforts to deploy a vaccine strategically. A SPR sensor coated with a peptide monolayer and functionalized with SARS-CoV-2 nucleocapsid recombinant protein detected anti-SARS-CoV-2 antibodies in the nanomolar range. This bioassay was performed on a portable SPR instrument in undiluted human serum and results were collected within 15 minutes of sample/sensor contact. This strategy paves the way to point-of-care and label-free rapid testing for antibodies.


2010 ◽  
Vol 2 (4) ◽  
pp. 368 ◽  
Author(s):  
Xiuqian Jiang ◽  
Mark Waterland ◽  
Len Blackwell ◽  
Ashton Partridge

Sign in / Sign up

Export Citation Format

Share Document